Health

HER2 + Breast Cancer Complex Treatment Algorithm Dr. Hamilton

Erica P. Hamilton, MD, describes a complex treatment algorithm for HER2-positive breast cancer.

Erica P. Hamilton, MD, head of the Breast and Gynecologic Cancer Research Program and Principal Investigator at the Sarah Cannon Research Institute, discusses how we are advancing a complex treatment algorithm for patients with HER2-positive breast cancer. I will.

The current treatment algorithm for HER2-positive breast cancer patients is complex, and Hamilton added that there is no perfect choice in the third space and decisions should be based on each patient. Tucatinib (Tukysa) is approved for use after second line treatment if the patient has brain metastases. As such, Hamilton explains that this is a reasonable option for this patient population, regardless of whether the patient is receiving a second or third treatment.

In the absence of brain metastases, several other factors can be considered. Hamilton adds that it may be better to avoid fam-trastuzumab deruxtecan-nxki (Enhertu) when treating patients with lung disease. However, according to Hamilton, trastuzumab deluxtecan is a preferred option when the patient is in visceral crisis or when an immediate response needs to be elicited, because the overall response rate associated with the drug is impressive. I will. Hamilton says that Tucatini Bresimen could potentially be used if the patient does not have an incredibly high disease burden and they are doing well in treatment.

Treatment is not a one-size-fits-all answer. Hamilton concludes that he will do more to optimally determine available medications by assessing conversations with patients and subtle differences in symptoms.

ExBulletin

HER2 + Breast Cancer Complex Treatment Algorithm Dr. Hamilton